Log In
BCIQ
Print this Print this
 

ALN-AGT

  Manage Alerts
Collapse Summary General Information
Company Alnylam Pharmaceuticals Inc.
DescriptionSubcutaneous RNAi therapeutic against angiotensinogen (AGT)
Molecular Target Angiotensinogen (AGT)
Mechanism of ActionGene silencing
Therapeutic ModalityNucleic acid: Linear RNA
Latest Stage of DevelopmentPreclinical
Standard Indication Genitourinary (unspecified)
Indication DetailsTreat preeclampsia
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today